Henry Prince-Miles
305 Grattan Street
Melbourne, VIC 3000, Australia
Melbourne, VIC 3000, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Journal: HemaSphere
Published: March 26, 2024
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Journal: Nature medicine
Published: June 18, 2023
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Journal: Leukemia
Published: December 17, 2019
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Journal: Current oncology reports
Published: March 25, 2018
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Journal: Internal medicine journal
Published: November 30, 2017
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Journal: Journal of hematology & oncology
Published: July 21, 2017
The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: December 21, 2016
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Journal: British journal of haematology
Published: September 24, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026